➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Baxter
McKesson
AstraZeneca
Mallinckrodt

Last Updated: August 1, 2021

DrugPatentWatch Database Preview

Patent: 10,119,171

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,119,171
Title:Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
Inventor(s): Gomis; Roger (Barcelona, ES), Jean-Mairet; Joel (Barcelona, ES)
Assignee: InBioMotion S.L. (Barcelona, ES)
Application Number:15/183,419
Patent Claims:see list of patent claims

Details for Patent 10,119,171

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen XGEVA denosumab INJECTABLE; SUBCUTANEOUS 125320 002 2010-06-01 ⤷  Try it Free InBioMotion S.L. (Barcelona, ES) 2032-10-12 RX Orphan search
Amgen PROLIA denosumab INJECTABLE; SUBCUTANEOUS 125320 001 2010-06-01 ⤷  Try it Free InBioMotion S.L. (Barcelona, ES) 2032-10-12 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,119,171

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2014057357 ⤷  Try it Free
United States of America 10114022 ⤷  Try it Free
United States of America 11041213 ⤷  Try it Free
United States of America 11041861 ⤷  Try it Free
United States of America 2014105918 ⤷  Try it Free
United States of America 2015362495 ⤷  Try it Free
United States of America 2017121777 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
McKinsey
Medtronic
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.